BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mendonça MCP, Kont A, Aburto MR, Cryan JF, O'Driscoll CM. Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System. Mol Pharm 2021;18:1491-506. [PMID: 33734715 DOI: 10.1021/acs.molpharmaceut.0c01238] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Hunter WB, Cooper WR, Sandoval-mojica AF, Mccollum G, Aishwarya V, Pelz-stelinski KS. Improving Suppression of Hemipteran Vectors and Bacterial Pathogens of Citrus and Solanaceous Plants: Advances in Antisense Oligonucleotides (FANA). Front Agron 2021;3:675247. [DOI: 10.3389/fagro.2021.675247] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Mishra N, Ashique S, Garg A, Rai VK, Dua K, Goyal A, Bhatt S. Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases. Drug Discov Today 2022:S1359-6446(22)00003-4. [PMID: 35017085 DOI: 10.1016/j.drudis.2022.01.003] [Reference Citation Analysis]
3 Hunter WB, Wintermantel WM. Optimizing Efficient RNAi-Mediated Control of Hemipteran Pests (Psyllids, Leafhoppers, Whitefly): Modified Pyrimidines in dsRNA Triggers. Plants (Basel) 2021;10:1782. [PMID: 34579315 DOI: 10.3390/plants10091782] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Goga A, Stoffel M. Therapeutic RNA-silencing oligonucleotides in metabolic diseases. Nat Rev Drug Discov 2022. [PMID: 35210608 DOI: 10.1038/s41573-022-00407-5] [Reference Citation Analysis]
5 Corey DR, Damha MJ, Manoharan M. Challenges and Opportunities for Nucleic Acid Therapeutics. Nucleic Acid Ther 2021. [PMID: 34931905 DOI: 10.1089/nat.2021.0085] [Reference Citation Analysis]
6 Mendonça MCP, Cronin MF, Cryan JF, O'Driscoll CM. Modified cyclodextrin-based nanoparticles mediated delivery of siRNA for huntingtin gene silencing across an in vitro BBB model. Eur J Pharm Biopharm 2021;169:309-18. [PMID: 34793942 DOI: 10.1016/j.ejpb.2021.11.003] [Reference Citation Analysis]
7 Bortolozzi A, Manashirov S, Chen A, Artigas F. Oligonucleotides as therapeutic tools for brain disorders: Focus on major depressive disorder and Parkinson's disease. Pharmacol Ther 2021;227:107873. [PMID: 33915178 DOI: 10.1016/j.pharmthera.2021.107873] [Reference Citation Analysis]
8 Raza F, Zafar H, Khan MW, Ullah A, Khan AU, Baseer A, Fareed R, Sohail M. Recent advances in the targeted delivery of paclitaxel nanomedicine for cancer therapy. Mater Adv . [DOI: 10.1039/d1ma00961c] [Reference Citation Analysis]
9 Arshad R, Fatima I, Sargazi S, Rahdar A, Karamzadeh-Jahromi M, Pandey S, Díez-Pascual AM, Bilal M. Novel Perspectives towards RNA-Based Nano-Theranostic Approaches for Cancer Management. Nanomaterials (Basel) 2021;11:3330. [PMID: 34947679 DOI: 10.3390/nano11123330] [Reference Citation Analysis]